EGFR and neoplasm: Primary resistance, or early tumor progression, is a common phenomenon where 20–30% of patients are insensitive to EGFR-TKIs from the beginning, despite the more prevalent acquired resistance to tumor-targeted therapies (Table 2) [4,6,7,8,9,10,113,114].